DMKJ
SYRS

David M. Knott Jr’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

David M. Knott Jr’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-233,000
Closed -$1.25M – 110
2024
Q1 		$1.25M Buy
233,000
+153,073
+192% +$1.06M 0.44% 39
2023
Q4 		$623K Sell
79,927
-26,048
-25% -$89.2K 0.24% 40
2023
Q3 		$419K Buy
105,975
+9,715
+10% +$36.4K 0.16% 57
2023
Q2 		$303K Buy
+96,260
New +$309K 0.12% 59

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

David M. Knott Jr's SYRS Position: Q2 2024 in Review

David M. Knott Jr sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2024, closing a stake of 233,000 shares — an estimated $1.25M sold.

David M. Knott Jr first reported a position in SYRS in Q2 2023 and held it in 4 quarters. The position peaked at $1.25M in Q1 2024. 70 funds tracked by Wall St. Rank hold SYRS as of Q2 2024.

  • David M. Knott Jr reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • David M. Knott Jr sold 233,000 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $1.25M.
  • David M. Knott Jr first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2023 and held it in 4 quarters.
  • David M. Knott Jr's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.25M in Q1 2024.
  • 70 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on David M. Knott Jr's 13F filing for Q2 2024, filed 12 Aug 2024.